Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Threshold Pharmaceuticals, a biotechnology company focused on the discovery and development of cancer drugs, has appointed Jeffrey Bird to its board of directors.
Subscribe to our email newsletter
The company has also announced that Michael Powell steps down from the company’s board of directors. Dr Bird will fill the seat held by Dr Powell, a board member since 2001.
Dr Bird will serve as a member of both the audit committee and the nominating and governance committee. Dr Bird was a co-founder of Threshold, led the company’s series A financing in 2001, and was formerly a Threshold board member from 2001 to 2004.
Barry Selick, CEO of Threshold, said: “We welcome Jeff Bird, who, in addition to his scientific insight, adds extensive strategic and operational experience to the collective knowledge of our board. At the same time, on behalf of the entire company, I want to extend gratitude to Mike Powell for his many valuable contributions to the company over the past seven years.”